Letters to the Editor

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study

National Clinical Research Center for Blood Diseases, State Key Laboratory of Blood Sciences, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang
First Affiliated Hospital, Zhejiang University College of Medicine, Hangzhou, Zhejiang
Peking University Third Hospital, Beijing
First Affiliated Hospital, Soochow University, Suzhou
First Affiliated Hospital, Xi’an Jiaotong University, Shaanxi
Sun Yat-sen University Cancer Center, Guangzhou
Johnson and Johnson, Beijing
Johnson and Johnson, Shanghai
Johnson and Johnson, Beijing
Johnson and Johnson, Beijing
Johnson and Johnson, Shanghai
Johnson and Johnson, Shanghai
Johnson and Johnson, Shanghai
Johnson and Johnson, Shanghai
Johnson and Johnson, Shanghai
Johnson and Johnson, Madrid, Spain
Johnson and Johnson, Spring House, PA
Johnson and Johnson, Spring House, PA
Johnson and Johnson, Raritan, NJ
Johnson and Johnson, Spring House, PA
Johnson and Johnson, Spring House, PA
Johnson and Johnson, Spring House, PA
National Clinical Research Center for Blood Diseases, State Key Laboratory of Blood Sciences, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin
Haematologica Early view Oct 9, 2025 https://doi.org/10.3324/haematol.2025.287334